Lobe Sciences Completes Debt Settlement to Improve Balance Sheet

Executive Summary

• Lobe Sciences Ltd. settled USD 137,130 (CAD 191,884.32) of related‑party liabilities by issuing 3,837,686 common shares at C$0.05 per share.
• The settlement improves the company’s balance sheet and preserves cash for growth initiatives.
• The transaction is a related‑party financing exempt from formal valuation and minority‑shareholder approval under MI 61‑101.

Key Details

• Settlement Amount: USD 137,130 (CAD 191,884.32).
• Shares Issued: 3,837,686 common shares (“Settlement Shares”).
• Issue Price: C$0.05 per share.
• Creditor: Clearway Global, LLC – a related party holding >20% of Lobe’s outstanding common shares and controlled by a director/officer.
• Statutory Hold Period: Four months from issuance under Canadian securities laws and CSE policies.
• Regulatory Exemption: Directors determined the settlement is exempt from MI 61‑101 valuation and minority‑shareholder approval requirements (sections 5.5(a) & 5.7(1)(a)).
• Use of Proceeds / Impact: Settlement eliminates the accounts payable to Clearway Global, strengthening balance sheet and freeing cash for strategic growth initiatives.
• Securities Offering Restrictions: Shares are not registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States or to U.S. persons absent an exemption.

Notable Quotes

• “Management remains focused on delivering long‑term growth and will continue to evaluate financing strategies that balance shareholder interests with operational needs.” – Dr. Fred D. Sancilio, CEO, Lobe Sciences Ltd.